AIM participates in the kick-off of the ASCERTAIN Horizon Europe project
On 24 and 25 January, AIM participated in the kick-off meeting of the Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise iNnovative health technologies (ASCERTAIN) consortium. ASCERTAIN is a project financed by the European Union’s research programme Horizon Europe. It will, among other things, develop new ways to calculate how to price new and expensive medicinal products, such as for instance gene and cell therapy.
The kick-off was the opportunity for consortium participants to meet in Rotterdam, where the meeting took place. During the first day of the meeting, participants discussed the overall organisation of the 4 years that the project will be running, as well remaining outstanding questions. The second day was dedicated to presentations from patients, payers and investors on their perspective related to access to medicines and how ASCERTAIN could help them better address their concerns. Another session during the day focused on initial feedback from consortium members on key pillars of the project: pricing, cost-effectiveness analysis, broad health technology assessment and reimbursement.
ASCERTAIN’s objective is to contribute, at the end of its four-year duration, to a better anticipation and calculation of pricing, HTA and reimbursement conditions for innovative health technologies (IHTs) for three disease areas: precision cancer medicines, cell and gene therapy as well as medical devices or in vitro diagnostics. Research and development costs will be among the elements that will be taken into account in these new calculation methods. Over the four years of the project, ASCERTAIN consortium members will look beyond the state-of-the art in terms of pricing and reimbursement models and policies, health technology assessment.
You can find AIM’s press release on ASCERTAIN here.